Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment
Paloma Sangro, Manuel de la Torre‐Aláez, Bruno Sangro, et al.
Journal of Physiology and Biochemistry (2023) Vol. 79, Iss. 4, pp. 869-879
Open Access | Times Cited: 66

Showing 1-25 of 66 citing articles:

Resmetirom: First Approval
Susan J. Keam
Drugs (2024) Vol. 84, Iss. 6, pp. 729-735
Closed Access | Times Cited: 89
Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options
Piero Portincasa, Mohamad Khalil, Laura Mahdi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5640-5640
Open Access | Times Cited: 21
Submicron Dispersions of Phytosterols Reverse Liver Steatosis with Higher Efficacy than Phytosterol Esters in a Diet Induced-Fatty Liver Murine Model
Raimundo Gillet, Tomás G. Cerda-Drago, María C. Brañes, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 2, pp. 564-564
Open Access | Times Cited: 2
Artificial intelligence in the management of metabolic disorders: a comprehensive review
A Anwar, Simran Rana, Priya Pathak
Journal of Endocrinological Investigation (2025)
Closed Access | Times Cited: 2
Underlying Mechanisms behind the Brain–Gut–Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update
Júlia Pauli De Cól, Enzo Pereira de Lima, Fernanda Moris Pompeu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3694-3694
Open Access | Times Cited: 12
Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma
Yumin Wang, Joshua S. Fleishman, Tongda Li, et al.
Frontiers in Pharmacology (2024) Vol. 14
Open Access | Times Cited: 11
Correlation analysis of the triglyceride–glucose index and related parameters in metabolic dysfunction-associated fatty liver disease
Xin Yang, Huiting Rao, Yi Yuan, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Thyme, oregano, and rosemary: herbs and food supplements for the management of metabolic associated fatty liver disease
Hamza Elbouny, Ayoub Amssayef, Rania Benjamaa, et al.
Nutrire (2025) Vol. 50, Iss. 1
Closed Access | Times Cited: 1
Novel Thiazolones for the Simultaneous Modulation of PPARγ, COX-2 and 15-LOX to Address Metabolic Disease-associated Portal Inflammation
Mai S. El-Shoukrofy, Azza Ismail, Reem H. Elhamammy, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117415-117415
Open Access | Times Cited: 1
Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)!
Hans-Jürgen Mohr, Jonathan G. Stine
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
Curcumin Analog J7 Attenuates Liver Fibrosis and Metabolic Dysregulation in a Rat Model of Type 2 Diabetes via Modulation of TGF-β/Smad and NF-κB/BCL-2/BAX Pathways
Jun Ma, Wei C., Deep K. Vaishnani, et al.
Drug Design Development and Therapy (2025) Vol. Volume 19, pp. 2411-2432
Open Access | Times Cited: 1
Molecular Aspects of MAFLD—New Insights on Pathogenesis and Treatment
Branka Filipović, Marija Marjanovic-Haljilji, Dragana Mijač, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 11, pp. 9132-9148
Open Access | Times Cited: 17
Transforming Screening, Risk Stratification, and Treatment Optimization in Chronic Liver Disease Through Data Science and translational Innovation
Tamer A. Addissouky
The Indonesian Journal of Gastroenterology Hepatology and Digestive Endoscopy (2024) Vol. 25, Iss. 1, pp. 53-62
Open Access | Times Cited: 6
Glucagon-like peptide 1 agonists are potentially useful drugs for treating metabolic dysfunction-associated steatotic liver disease
Maurizio Soresi, Lydia Giannitrapani
World Journal of Gastroenterology (2024) Vol. 30, Iss. 30, pp. 3541-3547
Open Access | Times Cited: 6
Hormone-based pharmacotherapy for metabolic dysfunction-associated fatty liver disease
Zara Siu Wa Chui, Yaqian Xue, Aimin Xu
Medical Review (2024) Vol. 4, Iss. 2, pp. 158-168
Open Access | Times Cited: 5
Links between fecal microplastics and parameters related to metabolic dysfunction-associated steatotic liver disease (MASLD) in humans: An exploratory study
Katherine J. P. Schwenger, Yasaman Ghorbani, Sharvika Bharatselvam, et al.
The Science of The Total Environment (2024) Vol. 953, pp. 176153-176153
Open Access | Times Cited: 5
Advances in genetic variation in metabolism-related fatty liver disease
Fan Shi, Mei Zhao, Shudan Zheng, et al.
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 11
Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study
So Hyun Cho, Seohyun Kim, Rosa Oh, et al.
Hepatology International (2024) Vol. 18, Iss. 4, pp. 1168-1177
Closed Access | Times Cited: 4
MAFLD Pandemic: Updates in Pharmacotherapeutic Approach Development
Farah Khaznadar, Omar Khaznadar, Ana G. Petrovic, et al.
Current Issues in Molecular Biology (2024) Vol. 46, Iss. 7, pp. 6300-6314
Open Access | Times Cited: 4
Hepatoprotective effect of the Sechium HD-Victor hybrid extract in a model of liver damage induced by carbon tetrachloride in mice
Eliana Vásquez Osorio, Ramírez-Padilla María-Guadalupe, Mendoza-Núñez Víctor-Manuel, et al.
Biomedicine & Pharmacotherapy (2025) Vol. 183, pp. 117831-117831
Open Access
Toxicological Assessment of Ketamine in Juvenile Zebrafish (Danio rerio)
Yin Tang, Yang Kang, Jintao Xu, et al.
Toxics (2025) Vol. 13, Iss. 2, pp. 82-82
Open Access
Effect of time-restricted feeding and caloric restriction in metabolic associated fatty liver disease in male rats
Jiang Deng, Juan Ma, Xin Zhang, et al.
Nutrition & Metabolism (2025) Vol. 22, Iss. 1
Open Access
Sex-specific effects of aged polystyrene microplastics on hepatic AMPK pathway activation and lipid droplet accumulation in MAFLD mice
Qing Wang, Xiaona Yang, Chuan Chen, et al.
Ecotoxicology and Environmental Safety (2025) Vol. 292, pp. 117963-117963
Open Access
Unlocking the potential of THR-β agonist therapies: resmetirom’s chemistry, biology, and patent insights
K. K. Dahiya, Mahesh B. Palkar, Sanjay Sharma
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access
Sleep Duration, Midpoint, Variability, Irregularity and Metabolic Dysfunction-Associated Steatotic Liver Disease
Qingcui Wu, Fuhai Song, Huijie Huang, et al.
Behavioral Sleep Medicine (2025), pp. 1-14
Closed Access
Page 1 - Next Page

Scroll to top